Upadacitinib — Membership Pricing

Other medications in Rheumatology

• Voclosporin
• Abatacept
• Anakinra
• Anifrolumab
• Baricitinib
• Belimumab
• Canakinumab
• Deucravacitinib

About Upadacitinib

Upadacitinib (brand name Rinvoq) is a targeted treatment offering significant relief for various chronic inflammatory conditions. As a specialty medication, its cost can be a concern for many. TheDrugClub is dedicated to helping members manage these expenses, providing pathways to potential savings and making essential treatments like upadacitinib more accessible.

Upadacitinib, marketed under the brand name Rinvoq, is a prescription medication used to treat a range of chronic inflammatory and autoimmune conditions. Originally approved for moderate to severe rheumatoid arthritis, its indications have expanded to include psoriatic arthritis, atopic dermatitis (eczema), ulcerative colitis, Crohn's disease, and ankylosing spondylitis. For individuals living with these conditions, upadacitinib offers a crucial therapeutic option, aiming to reduce symptoms, improve physical function, and enhance overall quality of life.

How Upadacitinib Works

Upadacitinib belongs to a class of drugs known as Janus kinase (JAK) inhibitors. JAK enzymes play a critical role in the signaling pathways that drive inflammation in the body. By selectively blocking the activity of specific JAK enzymes, upadacitinib helps to disrupt these inflammatory pathways. This targeted action reduces the overactive immune response that characterizes conditions like rheumatoid arthritis or Crohn's disease, leading to a decrease in pain, swelling, skin lesions, and other debilitating symptoms.

Understanding Typical Costs

As a cutting-edge, brand-name specialty medication, upadacitinib typically carries a significant cost. Without insurance or substantial financial assistance, the monthly out-of-pocket expense can run into thousands of dollars, making it a considerable

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

Boxed warning for Upadacitinib (FDA label)

WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS, and THROMBOSIS SERIOUS INFECTIONS Patients treated with RINVOQ /RINVOQ LQ are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions ( 5.1 ), Adverse Reactions ( 6.1 )]. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. If a serious infection develops, interrupt RINVOQ /RINVOQ LQ until the infection is controlled. Reported infections include: Active tuberculosis, which may present with pulmonary or extrapulmonary disease. Patients should be tested for latent tuberculosis before RINVOQ /RINVOQ LQ use and during therapy. Treatment for latent infection should be considered prior to RINVOQ /RINVOQ LQ use. Invasive fungal infections, including cryptococcosis and pneumocystosis. Bacterial, viral, including herpes zoster, and other infections due to opportunistic pathogens. The risks and benefits of treatment with RINVOQ /RINVOQ LQ should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection.

Source: FDA prescribing information (DailyMed). Set ID: 2966aec7-2ef0-923c-d8ff-fe1a957bf095. SPL document ID: e17266e5-c861-46bf-9756-6447566101be. Label effective date: June 30, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Upadacitinib (FDA label)

RINVOQ extended-release tablets: 15 mg upadacitinib: purple, biconvex oblong, with dimensions of 14 x 8 mm, and debossed with ‘a15’ on one side. 30 mg upadacitinib: red, biconvex oblong, with dimensions of 14 x 8 mm, and debossed with ‘a30’ on one side. 45 mg upadacitinib: yellow to mottled yellow, biconvex oblong, with dimensions of 14 x 8 mm, and debossed with ‘a45’ on one side. RINVOQ LQ oral solution: 1 mg/mL upadacitinib; clear, colorless to light yellow solution in bottle of 180 mL. RINVOQ extended-release tablets: 15 mg, 30 mg, and 45 mg ( 3 ) RINVOQ LQ oral solution: 1 mg/mL ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 2966aec7-2ef0-923c-d8ff-fe1a957bf095. SPL document ID: e17266e5-c861-46bf-9756-6447566101be. Label effective date: June 30, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Upadacitinib (FDA label)

The following clinically significant adverse reactions are described elsewhere in the labeling: Serious Infections [see Warnings and Precautions ( 5.1 )] Mortality [see Warnings and Precautions ( 5.2 )] Malignancy and Lymphoproliferative Disorders [see Warnings and Precautions ( 5.3 )] Major Adverse Cardiovascular Events [see Warnings and Precautions ( 5.4 )] Thrombosis [see Warnings and Precautions ( 5.5 )] Hypersensitivity Reactions [see Warnings and Precautions ( 5.6 )] Gastrointestinal Perforations [see Warnings and Precautions ( 5.7 )] Hypoglycemia in Patients with Diabetes [see Warnings and Precautions ( 5.8 )] Laboratory Abnormalities [see Warnings and Precautions ( 5.9 )] Rheumatoid arthritis , psoriatic arthritis , ankylosi ng spondylitis , and n on-radiographic a xial s pondyloarthritis : Adverse reactions (≥ 1%) were: upper respiratory tract infections, herpes zoster, herpes simplex, bronchitis, nausea, cough, pyrexia, acne, and headache. ( 6.1 ) Giant cell arteritis : Adverse reactions (≥ 5%) are upper respiratory tract infections, headache, fatigue, peripheral edema, cough, anemia, rash, herpes zoster, and nausea. ( 6.1 ) Atopic d ermatitis : Adverse reactions (≥ 1%) are: upper respiratory tract infections, acne, herpes simplex, headache, blood creatine phosphokinase increased, cough, hypersensitivity, folliculitis, nausea, abdominal pain, pyrexia, increased weight, herpes zoster, influenza, fatigue, neutropenia, myalgia, and influenza like illness. ( 6.1 ) Ulcerative colitis : Adverse reactions (≥ 5%) reported during induction or maintenance are: upper respiratory tract infections, increased blood creatine phosphokinase, acne, neutropenia, elevated liver enzymes, pyrexia, and rash. ( 6.1 ) Crohn’s disease : Adverse reactions (≥ 5%) reported during induction or maintenance are: upper respiratory tract infections, anemia, pyrexia, acne, herpes zoster, and headache. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact AbbVie Inc. at 1-800-633-9110 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 2966aec7-2ef0-923c-d8ff-fe1a957bf095. SPL document ID: e17266e5-c861-46bf-9756-6447566101be. Label effective date: June 30, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Upadacitinib (FDA label)

RINVOQ/RINVOQ LQ is contraindicated in patients with known hypersensitivity to upadacitinib or any of its excipients [see Warnings and Precautions ( 5.6 )] . Known hypersensitivity to upadacitinib or any of the excipients in RINVOQ/RINVOQ LQ. ( 4 , 5.6 )

Source: FDA prescribing information (DailyMed). Set ID: 2966aec7-2ef0-923c-d8ff-fe1a957bf095. SPL document ID: e17266e5-c861-46bf-9756-6447566101be. Label effective date: June 30, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Upadacitinib (FDA label)

Serious Infections : Avoid use in patients with active, serious infection, including localized infections. ( 5.1 ) Hypersensitivity : Serious hypersensitivity reactions (e.g., anaphylaxis) have been reported. Discontinue if a serious hypersensitivity reaction occurs. ( 5.6 ) Gastrointestinal (GI) Perforations : Monitor patients at risk for GI perforations and promptly evaluate patients with symptoms. ( 5.7 ) Hypoglycemia in Patients with Diabetes: Consider increased monitoring of blood glucose; advise patients with diabetes to notify their healthcare provider if they develop signs or symptoms of hypoglycemia. ( 5.8 ) Laboratory Abnormalities : Monitoring recommended due to potential changes in lymphocytes, neutrophils, hemoglobin, liver enzymes and lipids. ( 5.9 ) Embryo-Fetal Toxicity : May cause fetal harm based on animal studies.

Source: FDA prescribing information (DailyMed). Set ID: 2966aec7-2ef0-923c-d8ff-fe1a957bf095. SPL document ID: e17266e5-c861-46bf-9756-6447566101be. Label effective date: June 30, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Upadacitinib (FDA label)

Strong CYP3A4 Inhibitors : See the Full Prescribing Information for dosage modification for patients with atopic dermatitis, ulcerative colitis, and Crohn’s disease. ( 2.13 , 7.1 ) Strong CYP3A4 Inducers : Coadministration of RINVOQ/RINVOQ LQ with strong CYP3A4 inducers is not recommended. ( 7.2 ) 7.1 Strong CYP3A4 Inhibitors Upadacitinib exposure is increased when it is co-administered with a strong CYP3A4 inhibitor (such as ketoconazole, clarithromycin, and grapefruit), which may increase the risk of adverse reactions [see Clinical Pharmacology ( 12.3 )] . Monitor patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondylarthritis, pJIA, or giant cell arteritis closely for adverse reactions when co-administering RINVOQ/RINVOQ LQ with strong CYP3A4 inhibitors. Food or drink containing grapefruit should be avoided during treatment with RINVOQ/RINVOQ LQ. For patients with atopic dermatitis, coadministration of RINVOQ 30 mg once daily with strong CYP3A4 inhibitors is not recommended.

Source: FDA prescribing information (DailyMed). Set ID: 2966aec7-2ef0-923c-d8ff-fe1a957bf095. SPL document ID: e17266e5-c861-46bf-9756-6447566101be. Label effective date: June 30, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.